Oral semaglutide missed its primary endpoint for drinking. The VA’s new 622-person phase 3 is built on the one result that trial failed to get.
The fight that decides what you will pay for the strongest obesity drug yet seen in large trials comes down to a single amino acid, and nobody has won it yet.
I take a diabetes drug and have never had diabetes. A plain-English map of the type 2 diabetes drugs, and why the best ones now protect your heart and kidneys, not just blood sugar.
A BMJ analysis of 262 trials crowned tirzepatide the weight-loss king. But the drug with the hard survival and heart-attack data is the one that finished fifth.
A Yale secret-shopper study tried 49 direct-to-consumer GLP-1 sites. 45 wrote a prescription, some in five minutes. What the questionnaire mills skip, and how to spot real care.
The GLP-1 muscle loss panic scared me into training at 50. It turned out overblown, but the habit stuck. What the evidence actually says about muscle, and why you train after 50.
A research platform lets anyone turn health records into a publishable-looking study in an afternoon. Here is how that floods the GLP-1 and cancer literature, and how I read these studies now.
Retatrutide isn’t FDA approved, but it has a street name, a grey market with customer service, and Wall Street’s full attention. What the strongest weight-loss drug ever tested means, and why I’m not taking it.
A new study found people on GLP-1 drugs took fewer steps after starting. I lost the weight and moving got easier, so I went looking for why most people slow down.
The food noise went quiet. Then I had to rebuild the rest.
